Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. The focus of this study, seasonal allergic rhinitis (SAR), is one type of allergic rhinitis that is triggered by the pollen from trees, grasses, and weeds. Commonly referred to as "hay fever", it is characterized by sneezing, nasal congestion and pruritus, rhinorrhea, and pruritic, watery, red eyes. The purpose of this study is to evaluate the onset of action of an investigational nasal spray, GW685698X aqueous nasal spray, versus vehicle placebo nasal spray in the treatment of seasonal allergic rhinitis caused by ragweed following a single dose of treatment in controlled pollen concentrations in an allergen challenge chamber.

Randomized, Double Blind, Placebo-Controlled, Single-Dose, Parallel-Group Study to Evaluate the Onset of Action of a Single Dose of Intranasal GW685698X Aqueous Nasal Spray 100 mcg in Adolescent and Adult Subjects (=12 years of age) With Seasonal Allergic Rhinitis Exposed to Ragweed Pollen in an Allergen Challenge Chamber

Inclusion criteria:

• Informed consent
• Outpatient
• Females must use appropriate contraception
• Diagnosis of seasonal allergic rhinitis
• Able to comply with study procedures
• Literate

Exclusion criteria:

• Significant concomitant medical condition
• Use of corticosteroids, allergy medications, or tobacco
• Clinically significant abnormal ECG
• Laboratory abnormality
• Positive pregnancy test
• Allergy to any component of investigational product

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.